Bone marrow impairment during early [(177)Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?

BACKGROUND: The recent phase III VISION-trial confirms the treatment efficacy of radioligand therapy with [(177)Lu]PSMA-617 (PSMA-RLT) in metastatic castration-resistant prostate cancer (mCRPC). In PSMA-RLT, the relatively low absorbed bone marrow dose allows for multiple therapy cycles with relativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kind, Felix, Michalski, Kerstin, Yousefzadeh-Nowshahr, Elham, Meyer, Philipp T., Mix, Michael, Ruf, Juri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001754/
https://www.ncbi.nlm.nih.gov/pubmed/35403915
http://dx.doi.org/10.1186/s13550-022-00891-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001754/
https://www.ncbi.nlm.nih.gov/pubmed/35403915
http://dx.doi.org/10.1186/s13550-022-00891-1

Ejemplares similares